A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

NCT03239392 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bioniz Therapeutics